The human immune system is highly elaborated, with a diversity of stop and go mechanisms necessary to accomplish different tasks, encompassing clear "stop" situations, such as those needed to avoid fetal rejection during pregnancy, and permanent "go" status, necessary to combat infections by virus, bacteria, or fungi. Both mechanisms are in place or may be activated in a healthy organism, and distinction of "self" and "foreign" is essential to accomplish these tasks. Being cancer a disease generated by autologous cells, is it possible to teach the organism to fight it? In this review, which does not intend to be exhaustive, we shall discuss some of the most explored fields of research which aim to fight cancer through stimulating or inhibiting some specific targets of the immune system.

Immune Stimulation by Cancer Vaccines
=====================================

The rationale of using therapeutic vaccines in cancer began in the 1950s, when the fact that tumors express specific antigens (Ag) was demonstrated (Foley, [@B33]; Prehn and Main, [@B87]). Thus, immunity to cancer might be acquired, and the idea of developing cancer vaccines started. Most of the work in this field was performed on cutaneous melanoma (CM), which originates from melanocytes, melanin-containing cells that are responsible for pigmentation and protection against UV DNA damage, and it is a tumor with rising incidence worldwide (Siegel et al., [@B104]). Although CM is curable by surgical resection if detected in the early stages (Breslow Index \<2 mm depth), once it metastasizes its prognosis worsens, and it is refractory in the long-term to most current therapies (Gray-Schopfer et al., [@B44]). Different lines of evidence suggested that CM is an immunogenic tumor, mainly demonstrated by the existence of regressions in primary tumors and by the correlation between the presence of "brisk" lymphocytic infiltrates in primary tumors and longer survival (Clemente et al., [@B20]). Early work on CM vaccines was performed by Morton et al. ([@B78], [@B77]), Seigler et al. ([@B103]), and by Berd and Mastrangelo ([@B7],[@B8]), who used autologous irradiated melanoma cells as vaccines. After these pioneer attempts, several melanocytic differentiation Ag (MD-Ag) were discovered, such as MelanA/MART-1 (MART-1; Coulie et al., [@B22]; Kawakami et al., [@B60]), gp100/PMEL17/silver (gp100; Kawakami et al., [@B61]), tyrosinase (Brichard et al., [@B12]); tyrosinase-related protein-2 (trp-2; Wang et al., [@B125]), MELOE-1 (Godet et al., [@B42]), and a group of cancer-testis Ag (CT-Ag), such as the MAGE super-family and NY-ESO-1 (van der Bruggen et al., [@B120]; Chen et al., [@B17]). Besides these Ag, recent genomic work performed in human CM revealed dozens of mutations present in the melanoma genome, many of them residing in exons (Chin et al., [@B18]; Dutton-Regester and Hayward, [@B28]). The development of new high-throughput technologies, such as next-generation sequencing, will lead to a better knowledge of the battery of mutations present in different types of cancer and, particularly, in each patient. Somatic mutations that occur with very low frequencies may be detected, as well as other types of aberrations, including translocations and epigenetic changes (Ross and Cronin, [@B97]). Castle et al. ([@B13]) identified somatic point mutations in B16F10 murine melanoma cell line using next-generation sequencing. Immunogenicity of 50 validated mutations was assayed by immunizing mice with peptides encoding for the mutated epitopes, founding that one third of them were immunogenic.

Therefore, and considering the failure of most chemotherapeutic treatments, immunotherapy presents as a promising option. Until recently, the still fully unanswered question was whether humoral or cellular immune response would be more convenient to eradicate tumors in general and CM in particular. In a phase III randomized clinical study performed in 880 CM patients, a vaccine of GM2 ganglioside coupled to Keyhole Limpet Hemocyanin and using QS-21 as adjuvant, which induced IgM and IgG antibodies, was compared with high-dose interferon-alfa. The vaccination arm did worse than the interferon arm, and the assay was interrupted before completion (Kirkwood et al., [@B65]). However, when the effort was placed in the stimulation of cellular immunity, initial results were also disappointing. Thus, several clinical trials in stages IIB--IV CM patients utilizing vaccination with multiple peptides derived from MD-Ag (MART-1, gp100, and tyrosinase), and from CT-Ag (MAGE), had also limited success in CM patients (Rosenberg et al., [@B96]; Terando et al., [@B115]; Slingluff et al., [@B105]). It appears clear therefore that the optimal delivery of tumor Ag, in the presence of appropriate adjuvants, has not yet been found. In view of the multiplicity of possible Ag present in CM, mutated, and non-mutated, an approach has been to use vaccines consisting of irradiated whole tumor cells, which contain most of tumor Ag, giving the immune system the opportunity to process all of them (Barrio et al., [@B6]; von Euw et al., [@B122], [@B123]). The rationale assumption is that vaccination with a single or a few tumor Ag would not be sufficient to eradicate tumors, even if CD8+ and CD4+ cells are generated and are efficient in killing Ag-positive tumor cells, since we and others have shown that Ag-negative cells are present in most primary and metastatic CM and would soon repopulate the tumor (Koebel et al., [@B67]; Aris et al., [@B1]). The original approach of using autologous cells as vaccines (Berd and Mastrangelo, [@B7]) has two major disadvantages: first, patients must have heavy metastatic disease to obtain enough cells after surgery to manufacture vaccines, and are therefore relatively advanced stage of the disease; second, reproducibility in vaccine preparation is difficult to attain, since different patients have different tumor masses and cell yields are quite diverging. A significant advance in the vaccination field was achieved when it was demonstrated that the addition of the cytokine GM-CSF to vaccines increased the immune response against tumors (Dranoff et al., [@B25]). Several clinical trials have thereafter used GM-CSF to increase immunogenicity. Luiten et al. ([@B74]) used autologous melanoma cells transduced with a GM-CSF-producing retrovirus, and observed in some patients that tumor sites became infiltrated with lymphoid cells. Also, Soiffer et al. ([@B106]) used as vaccines irradiated autologous melanoma cells transduced with an adenovirus containing the GM-CSF gene. In this trial, immune reactivity at tumor sites was also observed, but all tested patients developed anti-adenovirus antibodies. We therefore decided to use as therapeutic vaccine a mixture of irradiated allogeneic melanoma cell lines, with BCG as adjuvant and injecting at the vaccination site GM-CSF coincidently with the vaccines; in this way we could exactly determine the amount of injected GM-CSF, and thus avoid the uncertainty of the amount and length of GM-CSF production by irradiated tumor cells. Using this approach in a Phase I clinical trial including 20 CM patients in stages III and IV, we obtained 70% of relapse-free survivors in stage III CM patients after a median follow-up of 106 months (Barrio et al., [@B6]). A similar vaccine (CSF 470) is now being assayed in a randomized Phase II/III clinical study, in which CSF470 plus GM-CSF and BCG as adjuvants is compared with IFN-alfa in stages IIB, IIC, and III CM patients.

The overall evidence has been shifting to the concept that immunity against CM should rely more on the development of specific CD8 and CD4 cells rather than on antibodies. The rationale of vaccination with tumor Ag, either in the form of Ag peptides, whole tumor cells, or cell lysates, is that such Ag should be captured by dendritic cells (DC), first described by Steinman and Cohn ([@B110]) in murine lymphoid organs, and later found to be potent stimulators of naïve lymphocytes (Steinman and Witmer, [@B111]). Subsequent work demonstrated that DC participate in the afferent and efferent limbs of the immune response, each requiring Ag presentation and MHC restriction. When studying Langerhans cells, a distinct type of DC present in epidermis, Schuler and Steinman ([@B101]) demonstrated that DC may exist in two states: immature DC, which are able to phagocytose Ag but not to process and present them to naïve lymphocytes, and mature DC, which have lost the ability to capture Ag but present processed Ag with great efficacy. The generally accepted pathways that DC use to activate naïve lymphocytes involves several steps: (i) capture of Ag in the periphery; (ii) maturation and migration of DC to draining lymph nodes; (iii) settling of DC in the lymph nodes and activation of naïve lymphocytes. Some of these steps have been analyzed to some detail in mice, although evidence in humans is still lacking. Thus, Eggert et al. ([@B30]) demonstrated that only about 1% of subcutaneously injected DC migrate to lymph nodes, although resident Langerhans cells, after immunization *in vivo*, migrate in high numbers to lymph nodes and persist there for about 2 weeks (Garg et al., [@B39]). It may be thus concluded that *in vivo* migration of DC is substantially more efficient than migration after DC production *in vitro* and subcutaneous injection, which could hamper vaccination attempts with DC loaded with tumor Ag. After this scarce migration of injected DC to regional lymph nodes, they must still overcome another difficulty: to find the appropriate T cells expressing the adequate TCR while maintaining bound to their HLA molecules the Ag peptides long enough to induce long-lasting contacts (Hugues et al., [@B54]). In fact, a clinical study comparing DC charged with tumor peptides or cell lysates demonstrated that only the latter were capable of inducing immune responses (Hersey et al., [@B47]). An explanation for these results came recently, since it has been shown that Ag peptides induced a quicker and stronger, but less prolonged response, than larger Ag peptides that are taken up by DC and degraded inside the cells (Faure et al., [@B32]). Recently, several approaches have taken profit of the ability of DC to capture foreign Ag, among them tumor Ag, and present them to naïve lymphocytes (Goldszmid et al., [@B43]; Liu et al., [@B71]). In humans, Palucka et al. ([@B82]) demonstrated that autologous DC were able to capture killed cells from an allogeneic tumor cell line and induce CD8+ T cell responses in 20 stage IV CM patients, leading to one complete and one partial response. Our group has demonstrated that autologous DC could capture a mixture of apoptotic and necrotic allogeneic melanoma cells, subsequently mature and cross-present MD-Ag to CD8 T cell clones (von Euw et al., [@B122]). von Euw et al. ([@B123]) also performed a clinical study in CM patients demonstrating that up to 1% anti-MART-1 and anti-gp100 CD8 T cell lymphocytes could be found in circulating blood after vaccination. Although 80% of Stage III patients attained a disease-free survival longer than 116 months, all stage IV patients relapsed. None of the approaches used so far could demonstrate that injected DC charged with apoptotic/necrotic tumor cells in humans are able to migrate efficiently to draining lymph nodes and establish a correct communication with naïve lymphocytes. The duration of the *in vivo* tumor Ag exposure by DC has also not been thoroughly studied in humans, as well as the number of CD8 cytotoxic T cells formed. A selection of different completed phase III clinical trials consisting in immunotherapeutic approaches against melanoma is shown in Table [1](#T1){ref-type="table"}.

###### 

**Immunotherapies against cancer: completed phase III clinical trials in CM**.

                                                                                                    Type of treatment                              Type of cancer   Clinical trial phase                       Adjuvants used                                                    Clinical results obtained
  ------------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------- ------------------------------------------ ----------------------------------------------------------------- ----------------------------------------------------------
  Enhancing immune response                                                                         **Ganglioside vaccine**                                                                                                                                                      
  GMK vs. high-dose IFN-alpha2b (HDI) E1694                                                         Melanoma stages IIb/III                        III              KLH -- QS-21                               PFS and OS benefit with HDI vs. GMK                               Kirkwood et al. ([@B65])
  **Peptide vaccines**                                                                                                                                                                                                                                                           
  Gp100 vaccine + high dose IL-2 vs. high dose IL-2 NCT00019682                                     Melanoma stage IV and unresectable stage III   III              IFA (Montanide ISA 51)                     Longer PFS vs. high dose IL-2, no significant improvement in OS   Schwartzentruber et al. ([@B102])
  Vitespen (autologous tumor-derived heat shock protein gp96 peptide complex vaccine) NCT00039000   Melanoma stage IV                              III              None                                       No changes in OS vs. physician choice                             Testori et al. ([@B116])
  **Whole cell vaccines**                                                                                                                                                                                                                                                        
  Canvaxin + BCG vs. placebo + BCG NCT00052156                                                      Melanoma stage IV                              III              BCG                                        No change in OS vs. BCG                                           Commented in Sondak et al. ([@B108]), Dalgleish ([@B24])
  Countering immunosuppression                                                                      **CTLA-4**                                                                                                                                                                   
  Ipilimumab vs. Ipilimumab + gp100 vs. gp100 NCT00065442                                           Melanoma stage IV and unresectable stage III   III              IFA (Montanide ISA-51) in vaccine groups   Improved OS ipilimumab alone or +gp100 vs. gp100 alone            Hodi et al. ([@B51])
  Ipilimumab + dacarbazine vs. placebo + dacarbazine NCT00324155                                    Melanoma stage IV and unresectable stage III   III              None                                       Longer OS with ipilimumab + dacarbazine                           Robert et al. ([@B95])

*PFS, progression free survival; OS, overall survival*.

Up to date, the only vaccine approved for cancer treatment is Provenge (sipuleucel-T), a vaccine for advanced prostate cancer which consists of a mixture of peripheral blood mononuclear cells exposed to prostatic acid phosphatase fused to GM-CSF. In a phase III clinical trial, the use of Provenge prolonged overall survival in patients with metastatic castration-resistant prostate cancer (Kantoff et al., [@B59]), but no effect on time to disease progression was observed. Provenge hypothesized mechanism for antitumor activity is that Ag-presenting cells (APC) process and present the recombinant Ag on their surface. After being reinfused into the patient, these cells could activate T cells that recognize the specific Ag and, therefore, stimulate them to attack prostatic acid phosphatase-positive prostate cancer cells (Sonpavde et al., [@B109]). This proposed mechanism requires further validation. There are several critiques to this vaccine related with the fact that improved overall survival was not accompanied with measurable antitumor effect and with the lack of supportive evidence for the mechanism proposed. After reanalysis of phase III data and of previously unpublished data obtained from FDA documents, Huber et al. ([@B53]) made some concerns about this recently approved vaccine. In the first place, unexpected interactions between patient age and survival were found: an 11-month difference in median overall survival between placebo patients younger and older than 65 years was observed, and sipuleucel-T treatment appeared to have only a positive effect in survival of older patients. These results were unexpected because age is not a prognostic factor in castration-resistant prostate patients under chemotherapeutic treatment and immunotherapies should be more effective in younger patients. Other important point is that patients in the placebo group appeared to have shorter overall survival than might be expected from other studies, which led to think that placebo treatment is actually an inappropriate control for sipuleucel-T. Huber et al. also discussed the manufacture protocol of the vaccine and the placebo, suggesting that the placebo protocol included steps that could contribute to cell killing and therefore, injection of dead cells in patients of the placebo arm could lead to a reduction in overall survival (OS).

Besides this vaccine in particular, the reasons that could explain why therapeutic cancer vaccines do not act as well as expected are multiple. Finding the right adjuvants and countering immunosuppression are possible keys to bypass such limitations.

Adjuvants
=========

A successful vaccination requires the addition to the desired Ag of adjuvants, which serve as amplifiers of the immune response. Adjuvants for clinical use must equilibrate efficacy with safety, although this balance should also integrate the purpose of vaccination: it is not the same scenario to vaccinate preventively millions of people against a viral disease such as influenza, than to vaccinate therapeutically a much more limited population with cancer, as would be the case of CM patients. In the latter case, a certain degree of toxicity of the adjuvants could be tolerated if the antitumor effect of vaccines is enhanced. We are still largely ignorant of the mechanism of action of adjuvants. The extremely potent complete Freund adjuvant (CFA) and incomplete Freund adjuvant (IFA) have been used for decades (Freund, [@B38]), but in spite of their potency, their use is not allowed in humans due to toxicity, since they may lead to harmful local injuries and autoimmune diseases. Essentially, IFA is paraffin oil suspended in water, and in addition, CFA contains heat-killed *Mycobacteria*, usually *M. tuberculosis*. Although used by immunologists for decades, the mechanisms of action of IFA and CFA are barely understood and are still being analyzed (Billiau and Matthys, [@B10]). Since IFA and CFA are potent but toxic, mineral oil has been replaced by terpenoids, among them the lipophilic substance squalene, a triterpene found in the adjuvants MF59 and AS03. Both have been used in clinical trials with a good safety profile and have been approved in Europe and conditionally approved in the US as stockpiled adjuvants in the pandemic influenza (Fox et al., [@B37]). Montanide™ incomplete Seppic adjuvant (ISA) 51 and 720 are water-in-oil emulsions similar to IFA that are under investigation for their use in humans. Montanide™ ISA 51 contains a mannide monooleate emulsifier and a degradable mineral oil, which has been demonstrated to be non-carcinogenic, non-teratogenic, and non-mutagenic. To improve safety, the mineral oil has been switched in Montanide™ ISA 720 to the metabolizable squalene oil (Aucouturier et al., [@B4]).

Also, QS-21, a water-soluble triterpene glycoside, has been used in clinical trials (Soltysik et al., [@B107]; Livingston et al., [@B72]; Kensil and Kammer, [@B63]). Novel isoprenoid immunostimulants, such as those phytol-derived, are also being analyzed (Chowdhury and Ghosh, [@B19]).

Aluminum salt/gel-based (Alum) adjuvants are approved for clinical use in the US and have been used for many years as immunopotentiator for vaccines, being particularly effective to promote protective humoral immunity (Schijns and Lavelle, [@B99]). However, Alum adjuvants do not induce a T helper type 1 cell-mediated immune response.

A great input to understand the mechanism of action of adjuvants came after the seminal finding by Hoffman's group of the immune function of Toll receptors in flies (Lemaitre et al., [@B69]). The identification of toll like receptors (TLR) in mammals, of which more than 10 different varieties are now recognized, paved the way to understand the importance of the innate immune response to Ag, and the subsequent interactions between the innate and adaptive immune system (Medzhitov et al., [@B75]). Specially important was the finding by Beutler's group that TLR4 recognizes pathogen-associated molecular patterns (PAMPS) such as those present in the bacterial lipopolysaccharide (LPS; Poltorak et al., [@B85]). From that point on, the appropriate search and use of adjuvants has acquired a more rational basis (for a review, see Duthie et al., [@B26]). Other mechanisms of TLR recognition of foreign molecules, such as TLR3 binding of double-stranded RNA present in virus, have been discovered and originated the synthetic adjuvant double-stranded RNA polyriboinosinic--polyribocytidylic acid (poly I:C; Trumpfheller et al., [@B119]).

T~reg~: Implications for Immunotherapy
======================================

Regulatory T (T~reg~) cells are a subpopulation responsible for controlling immune homeostasis, maintaining T cell tolerance to self Ag. T~reg~-mediated immunosuppression is thought to be one of the most important mechanisms of tumor immune evasion and probably a main obstacle for effective cancer immunotherapies (Zou, [@B130]).

T~reg~ represent 5--10% of the CD4 T cells in peripheral blood (Loser and Beissert, [@B73]). They are characterized by the constitutive expression of CD25 (IL-2 receptor alpha-chain) and by the expression of the transcription factor forkhead box P3 (FOXP3), crucial for T~reg~ development and function (Fontenot et al., [@B35]).

T~reg~ are augmented in peripheral blood of CM patients (Cesana et al., [@B14]; Jandus et al., [@B57]; Correll et al., [@B21]) and they are also highly enriched in the tumor microenvironment (Jacobs et al., [@B55]) exerting an immunosuppressive function (Javia and Rosenberg, [@B58]; Vence et al., [@B121]). In tumor infiltrating lymphocytes (TIL) from different types of tumors, T~reg~ were identified as they expressed CD25, FOXP3 and glucocorticoid-induced tumor necrosis factor receptor (GITR) and presented a suppressive function (Wang et al., [@B124]; Kiniwa et al., [@B64]).

Curiel et al. ([@B23]) reported that accumulation of T~reg~ in the tumor microenvironment was associated with death hazard and reduced survival of ovarian cancer patients. However, the correlation between T~reg~ and prognosis in CM patients is still under debate. Some studies showed that an elevated percentage of T~reg~ in primary melanoma and metastasis predicted recurrence and reduced overall survival (Miracco et al., [@B76]; Knol et al., [@B66]), while others did not found such correlation (Hillen et al., [@B48]; Ladanyi et al., [@B68]).

T~reg~ can be classified in natural T~reg~ (nT~reg~) and inducible T~reg~ (iT~reg~). nT~reg~, CD4+/CD25+ FOXP3+, are selected by the thymus and are responsible of maintaining peripheral self-tolerance. They mediate immunosuppression by cell contact-dependent mechanisms (Raimondi et al., [@B91]). iT~reg~, also referred as Tr1, are induced in the periphery by environmental signals. Their mode of action is through IL-10 and TGF-beta, so they act in a contact-independent way (Chattopadhyay et al., [@B16]) and they may not express FOXP3. T~reg~ present in cancer patients are predominantly iT~reg~ (Whiteside, [@B127]), that mediate stronger suppression and might use additional suppression mechanisms than nT~reg~ (Strauss et al., [@B112]).

T~reg~ and T helper cells can be both stimulated by the same melanoma-associated Ag (Fourcade et al., [@B36]). Because of this, inactivation or depletion of T~reg~ may be useful in combination with vaccination to obtain a successful immunotherapy response. T~reg~ depletion therapies include treatment with cyclophosphamide (Ghiringhelli et al., [@B41]), anti-CD25 antibodies, and toxins fused to anti-CD25 antibodies or IL-2 (Powell et al., [@B86]; Jacobs et al., [@B56]), and FOXP3 vaccination (Nair et al., [@B79]). With the aim of developing efficient T~reg~-targeting strategies, it is essential to find new and more accurate markers to characterize T~reg~.

CTLA-4 and Its Role in Down-Modulating the Immune Response
==========================================================

In order to boost the activity of therapeutic cancer vaccines, it is important to understand the mechanisms which counter the building-up of a solid immunity in cancer patients. One of such mechanisms is the presence in T lymphocytes of the inhibitory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4), a type I transmembrane glycoprotein that presents homology with CD28 (Teft et al., [@B114]). CTLA-4 is expressed in activated T cells and constitutively in T~reg~ and, as CD28, it binds to B7.1 (CD80) and B7.2 (CD86) present in APC, but with greater affinity and avidity. CTLA-4 has an inhibitory role in T cell activation, and its expression and localization are tightly regulated in T cells. After activation, CTLA-4 expression increases, reaching a maximum after 2--3 days, and it is translocated to its active localization at the cell surface (Egen et al., [@B29]). CTLA-4 function is essential to the maintenance of immune homeostasis and helps tolerance to self Ag by downregulating T cell response and proliferation. CTLA-4-deficient mice die from profound lymphoproliferative disease, with multiorgan lymphocytic infiltration, and tissue destruction (Tivol et al., [@B117]; Waterhouse et al., [@B126]). However, mixed bone marrow chimeric mice that have both CTLA-4^−/−^ and normal T cells do not present the lymphoproliferative disorder observed in CTLA-4-deficient mice (Bachmann et al., [@B5]), suggesting that CTLA-4 function has a non-cell autonomous component acting in *trans*. Different possibilities have been proposed to explain CTLA-4 mechanism of action. In the first place, CTLA-4 competes with CD28 for its ligands CD80 and CD86. Since both ligands have higher affinity for CTLA-4, it abolishes CD28 signaling, therefore mediating an indirect effect. Besides, CTLA-4 sends cell-intrinsic *cis* negative signals through its cytoplasmic domain, inhibiting different components of the cell cycle machinery (Greenwald et al., [@B45]) and blocking TCR and CD28 signaling (Teft et al., [@B114]). CTLA-4 may also function by disrupting the organization of molecules in the immune synapse (Chambers et al., [@B15]). Additional potential CTLA-4 functions include upregulation of indolamine 2,3-dioxygenase (IDO) activity in APCs via CD80 and CD86 and regulation of T cell adhesion to APCs (Schneider et al., [@B100]; Sansom and Walker, [@B98]). Besides, evidence in mice suggests that CTLA-4 is constitutively expressed in T~reg~ and would mediate T~reg~ immunosuppression (Takahashi et al., [@B113]; Wing et al., [@B128]), since blocking CTLA-4 in T~reg~ restrain their ability to inhibit T effector cell proliferation (Peggs et al., [@B84]). Recently, another cell extrinsic mechanism for CTLA-4 function was proposed, suggesting that it participates in the removal of costimulatory ligands via *trans*-endocytosis (Qureshi et al., [@B89]).

Two different models have been proposed to integrate the stimulatory signals involved in T cell activation and CTLA-4 function, the *threshold* and the *attenuation* models (Chambers et al., [@B15]). According to the threshold model, CTLA-4 would increase the minimum requirements for T cell activation by setting a threshold for the quantity and/or quality of TCR signal and/or costimulatory signals (Egen et al., [@B29]). The attenuation model proposes that CTLA-4 would exert its inhibitory function after T cell stimulation once the cell already entered cycling, and CTLA-4 levels would depend on strength of TCR signal.

CTLA-4 as Therapeutic Target
============================

Considering CTLA-4 key role in the regulation of T cell response, blocking antibodies have been developed in order to potentiate anticancer responses. Ipilimumab, a human IgG1 monoclonal antibody (mAb) anti-CTLA-4, and Tremelimumab, another human IgG2 mAb anti-CTLA-4, were tested in clinical trials in patients with CM (Ascierto et al., [@B2]).

By which mechanism CTLA-4 blocking antibodies exert their function is not completely clear. In murine models, CTLA-4 blockade leads to antitumor cytotoxicity, presenting an increased ratio of CD8:T~reg~ in tumor infiltrates (Quezada et al., [@B88]). Recently it has been proposed that CTLA-4 blockade could enhance memory CD8 T cell response (Pedicord et al., [@B83]), which could be important in cancer therapy to improve tumor-specific memory CD8 T cells and develop durable anticancer responses. Several early stage clinical trials demonstrated that CTLA-4 blockade alone or in combination with other therapies, as vaccines or chemotherapy, can induce tumor regression in a minority of metastatic CM patients (Hodi et al., [@B50]; Attia et al., [@B3]; Ribas et al., [@B93], [@B94]). Hodi et al. ([@B49]) showed that biopsies of metastatic melanoma lesions after ipilimumab administration showed dense infiltration of CD8 T cells, and tumor necrosis correlated with the ratio of infiltrating CD8 T cells/FoxP3+ cells. Blockade of CTLA-4 would promote T cell proliferation in lymphoid organs that would subsequently lead to an increased T-cell infiltration in most patients (Ribas et al., [@B92]; Huang et al., [@B52]). However, tumor infiltration by T cells does not correlate with patient's clinical response (Huang et al., [@B52]), suggesting that resistance to CTLA-4 blockade could depend on the immunosuppressive mechanisms that the tumor displays.

Last year, as a result of a phase III clinical trial (Hodi et al., [@B51]), USA FDA approved the use of ipilimumab for treatment of advanced metastatic CM. The antibody therapy, with or without gp100 peptide vaccine, showed improved overall survival compared to gp100 vaccine alone. Toxicity was found in patients treated with ipilimumab, including grades 3--4 immune-related adverse events (irAE) in 10--15% of patients.

Another phase III study of ipilimumab was performed in patients with previously untreated metastatic CM. In this case, ipilimumab in combination with dacarbazine was compared with dacarbazine plus placebo, showing improved overall survival with the antibody therapy (Robert et al., [@B95]). Remarkably, the time of ipilimumab to induce tumor remissions may take months, pointing to a different mechanism of action than most chemotherapeutic agents.

Other Inhibitory Coreceptors
============================

In addition, diverse targets are also being studied in order to potentiate antitumor immune response. Programmed (cell) death-1 (PD-1; CD279) is an inhibitory coreceptor which can be expressed in activated T cells, B cells, NK cells, activated monocytes, and DC (Keir et al., [@B62]). The ligands for PD-1, PD-L1 (B7-H1; CD274), and PD-L2 (B7-DC; CD273) are upregulated in response to inflammation. In fact, the major role of PD-1 is to limit the activity of T cells in the periphery during an inflammatory response to infection and autoimmunity (Topalian et al., [@B118]). The PD-1/PD-L1 pathway is important in the development of central and peripheral tolerance to exogenous Ag at sites of immune privilege, limiting the duration of the normal adaptive immune response (Folkl and Bienzle, [@B34]). Physiological functions of the PD pathway are altered in cancer (Okazaki and Honjo, [@B81]). Currently, there are four anti-PD-1 agents in clinical testing for cancer therapy: MDX-1106/BMS-936558/ONO-4538; CT-011; MK-3475, and AMP-224 (Topalian et al., [@B118]). MDX-1106 is a fully human IgG4 mAb that has been tested in a phase I clinical trial on 39 patients with treatment-refractory solid tumors. This mAb showed antitumor activity and was well tolerated. Pharmacodynamic studies indicated a sustained mean occupancy of around 70% on circulating T cells during 2 months. Approximately 12% of patients suffered grade ≥3 adverse clinical events (Brahmer et al., [@B11]). A randomized phase II study is currently undergoing to evaluate this mAb in metastatic renal cell carcinoma. CT-011, a humanized IgG1 mAb, was tested on 17 patients with advanced hematologic malignancies. This anti-PD-1 agent was generally well tolerated (Berger et al., [@B9]). CT-011 is currently undergoing a phase II clinical trial on metastatic renal cell carcinoma patients.

Low-Dose Cyclophosphamide
=========================

Another way of countering immune suppression is to use low doses of the alkylating agent cyclophosphamide (CTX). Already Berd and Mastrangelo ([@B8]) utilized low-dose CTX (300 mg/sq m) to diminish immune suppression in CM patients. This immune-enhancing effect of CTX was afterward analyzed in several experimental systems and using different CTX doses. The results obtained, although positive, point to different mechanisms of action. Thus, Ghiringhelli et al. ([@B40]) working on a rat colon carcinoma, demonstrated that a single injection of CTX (30 mg/kg) determined tumor rejection, and the authors attributed this effect to lymphodepletion of CD4+/CD25+ T~reg~. In the C57Bl/6J mice/B16 melanoma cells model, Nakahara et al. ([@B80]) found that a single injection of CTX (150 mg/kg) induced a selective and profound depletion of resident CD8+ DC, and that such depletion diminished the activity of T~reg~ and restored concommitant antitumor immunity. Pointing in the same direction, Radojcic et al. ([@B90]) demonstrated that a single injection of CTX (200 mg/kg) in mice bearing CT26 colon carcinoma would enhance antitumor immunity by resetting DC homeostasis.

Clinical trials using CTX to enhance antitumor immunity are scarce. Ghiringhelli et al. ([@B41]) used iterative low doses of CTX in advanced cancer patients and demonstrated a strong reduction of circulating T~reg~ However, Ellebaek et al. ([@B31]) in a phase II trial with CM patients using metronomic CTX, did not find any reduction in circulating T~reg~. Further clinical trials addressing the role of CTX to enhance antitumor immunity should be examined in carefully designed clinical trials.

Which Sleeping Lymphocytes Need to be Awaken to Exert Antitumor Effect?
=======================================================================

After the observed induction by anti-CTLA-4 mAb of immune responses against tumors, as well as of autoimmune reactions, the question may be posed if such effects are due to the emergence of effector T lymphocytes induced *de novo* by the derepression of T~reg~ on APC, or, alternatively, if CD4 and CD8 effector lymphocytes which are blocked in *cis* by CTLA-4 are already in the circulation and relieved from this suppression by ipilimumab. Besides, there is yet another question that remains to be answered: CD4 and CD8 cells generated by vaccination absolutely need to have high affinity or avidity toward tumor cells to be active? In this sense, it is important to note that Dutoit et al. ([@B27]) have shown that in preimmune HLA-A2 individuals, up to 1/1.000 CD8 lymphocytes recognized MART-1 peptides with low avidity (nM range), as compared to high affinities found for TCR directed to viral Ag (pM range), and that most of the CD8 clones exhibited cross-reactivity toward self-peptides (TCR polyspecificity; Dutoit et al., [@B27]). However, expansion of the naïve anti-MART-1 CD8 pool does not appear to play a role in tumor regressions induced by ipilimumab, since the outcome of HLA-A2-positive and -negative patients is similar (Wolchok et al., [@B129]). The polyspecificity of TCR has been studied in more detail in autoimmunity, in which several experimental models are available. In multiple sclerosis and Type 1 Diabetes, polyspecificity of the TCR, characterized by the ability of a single TCR to recognize diverse MHC-peptides, appears to be an intrinsic property of TCR (Liblau et al., [@B70]).

In the case of cancer, it is not yet known which are the TCR best suited to eliminate tumors in the long range: those with high affinity for a single HLA--peptide complex or those with medium affinity but directed against a variety of targets.

Another question that may be posed is the effective ability of CD8 T cells to lyse tumor cells. In this sense, the different contexts in which tumor cells and T lymphocytes may encounter should be differentiated. In the simplest case, that is, when cytotoxic lymphocytes (CTL) are confronted *in vitro* to tumor cells, we have shown that clonogenic melanoma cells are effectively lysed by anti-MART-1 and/or anti-gp100 CTL (Aris et al., [@B1]). However, if such activity is maintained *in vivo* has not been answered. Large tumors (\>2 cm) are presently considered as an organ, in which complex interactions between the tumor and stroma are established, and in which genomic instability and inflammation play substantial roles in favoring tumor progression. A complex array of immunosuppressive factors is released by tumor cells, building an immunoresistant superstructure (Hanahan and Weinberg, [@B46]). It is our view that large tumors display a setting in which vaccination has a limited role; the most amenable clinical context to assay antitumor vaccination, would be patients in which the existence of micrometastasis is highly probable. Under such circumstances, the tumor "fortress" building has not been completed, and the immune system has fewer obstacles to surmount. CM patients with stages II and III of the disease could benefit from such therapy. The use of agents which counter immunosuppression, such as ipilimumab, in combination with cancer vaccines, could lead to additive or synergistic responses.
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